Sigma Planning Corp Sells 22,684 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Sigma Planning Corp lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 57.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,969 shares of the biopharmaceutical company’s stock after selling 22,684 shares during the period. Sigma Planning Corp’s holdings in Gilead Sciences were worth $1,375,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. OFI Invest Asset Management bought a new position in shares of Gilead Sciences in the 3rd quarter worth $26,000. Tompkins Financial Corp increased its holdings in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the last quarter. Fortitude Family Office LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth $29,000. Rakuten Securities Inc. bought a new position in shares of Gilead Sciences in the 4th quarter worth $33,000. Finally, Financial Connections Group Inc. bought a new position in shares of Gilead Sciences in the 4th quarter worth $40,000. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on GILD. UBS Group decreased their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. StockNews.com lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday. Barclays reduced their target price on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a report on Monday, February 12th. Cantor Fitzgerald reduced their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and a consensus target price of $84.71.

Gilead Sciences Trading Up 0.3 %

Shares of GILD opened at $66.95 on Tuesday. The stock has a market capitalization of $83.36 billion, a P/E ratio of 14.88, a PEG ratio of 0.92 and a beta of 0.19. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The firm has a fifty day simple moving average of $71.81 and a two-hundred day simple moving average of $76.51. Gilead Sciences, Inc. has a twelve month low of $65.90 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. During the same period in the prior year, the business posted $1.67 earnings per share. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, research analysts anticipate that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.60%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.